The Achilles heel of TNBCs: Ferroptosis heterogeneity

Li Jiang; Xiao-Meng Gao; Ji Cao

doi:10.1016/j.cmet.2022.11.014

The Achilles heel of TNBCs: Ferroptosis heterogeneity

Cell Metab. 2023 Jan 3;35(1):1-2. doi: 10.1016/j.cmet.2022.11.014.

Authors

Li Jiang¹, Xiao-Meng Gao², Ji Cao³

Affiliations

¹ Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou 310018, China; Cancer Center of Zhejiang University, Hangzhou 310058, China.
² Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Cancer Center of Zhejiang University, Hangzhou 310058, China.
³ Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou 310018, China; Cancer Center of Zhejiang University, Hangzhou 310058, China. Electronic address: caoji88@zju.edu.cn.

PMID: 36599296
DOI: 10.1016/j.cmet.2022.11.014

Abstract

Resistance to ferroptosis, a form of programmed cell death, is associated with the development of some refractory cancers. In this issue, Yang et al. systematically illustrate the ferroptosis heterogeneity in triple-negative breast cancers (TNBCs) and reveal an innovative immunotherapy combination strategy for the luminal androgen receptor (LAR) subtype of TNBC.

Publication types

Comment

MeSH terms

Ferroptosis*
Heel
Humans
Immunotherapy
Triple Negative Breast Neoplasms* / metabolism